Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Incannex Healthcare Limited IXHL
$1.83
-$0.08 (-4.47%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
123151976.00000000
-
week52high
8.65
-
week52low
1.77
-
Revenue
0
-
P/E TTM
-9
-
Beta
1.75114500
-
EPS
-17.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 дек 2022 г. в 00:00
Описание компании
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. The company's products include IHL-42X, for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of cannabinoid for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, and asthma, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Clinical Psychedelic Research Lab at Monash University, to investigate the use of psilocybin assisted psychotherapy for treatment of Generalised Anxiety Disorder. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
08 сент 2022 г. в 09:15
MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.
5 Cannabis Stocks You Don't Want to Hit 'Snooze' On
Schaeffers Research
22 июл 2022 г. в 14:51
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
PRNewsWire
27 июн 2022 г. в 06:55
MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex's psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannex's psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022.
What Happened With These 11 Cannabis Stocks This Week?
Schaeffers Research
20 мая 2022 г. в 10:32
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
Incannex Healthcare rallies after airing plan to buy cannabis medicine company APIRx
Market Watch
24 мар 2022 г. в 08:47
Incannex Healthcare Ltd. IXHL, -4.23% shares jumped 7% after the Australia-based cannabinoid and psychedelic compound medicine development company said it would pay $93.3 million to acquire APIRx Pharmaceutical USA LLC, a pharmaceutical medicinal cannabinoid product development company.